A 40-Year-Old Company That Suddenly Found Its Growth Engine.

Some businesses take decades to create value.

Others take decades to prepare for a change in the business model.

Tanfac Industries is an interesting example of the latter.

It is a nearly 40-year-old company that delivered almost nothing for shareholders for close to two decades. Then, from 2022 onwards, the stock went on to deliver a 10x+ move in roughly four years.

So what changed?

The business did.

The real turning point was ownership:

Tanfac was historically a Tamil Nadu Government–Birla joint venture. That changed when Anupam Rasayan came in and acquired roughly 25% of the company.

This wasn’t just a change in shareholding.

Anupam Rasayan brought with it a much stronger specialty chemicals and R&D-oriented mindset, and the numbers started reflecting that.

Since the management change, Tanfac’s revenue has grown at roughly a 37% CAGR.

Interestingly, the company has only recently started holding regular quarterly earnings calls, so the story is still relatively under-covered.

And this is where the business gets interesting.

Tanfac sits at an important point in the fluorochemicals value chain:

The company imports sulfur and converts it into sulfuric acid, giving it backward integration.

Sulfuric acid then feeds into Hydrofluoric Acid (HF), which is the key product for Tanfac.

From here, HF goes in different directions.

Anhydrous HF is used in pharma intermediates, agrochemicals and refrigerants such as R32.

The other opportunity is solar-grade dilute HF (DHF), which is used for cleaning and etching silicon wafers used in solar cells.

And importantly, Tanfac is currently the only Indian producer of solar-grade DHF.

Today, roughly 85% of revenue comes from HF-based products, while the remaining ~15% comes from direct sulfuric acid sales.

But the next leg of the story could be much more valuable.

The R32 opportunity:

This is probably the most important part of the Tanfac story.

R32 is a hydrofluorocarbon refrigerant and has a significantly lower global-warming potential than many older refrigerants.

More importantly, it is becoming the primary choice for the HVAC industry, with India’s R32 market expected to grow at roughly 15% CAGR.

But the interesting part isn’t just demand.

It is capacity.

Under the Kigali Amendment, countries operate within a CO₂-equivalent-based quota for HFC production.

India’s estimated quota is around 110,000 MT per year.

Existing and already-announced capacity across listed Indian players is already around 113,000 MT per year.

That creates an unusual situation.

The industry is effectively building capacity against a constrained regulatory envelope.

For an incumbent like Tanfac, this can become a meaningful barrier to entry.

And Tanfac is now adding 20,000 MT/year of R32 capacity, expected to go live in Q3 FY27.

Even more interestingly, around 65% of this capacity is already pre-booked, with orders from a Japanese customer and a large multinational.

Production hasn’t even started yet.

And the economics improve as you move down the value chain:

This is perhaps the most important piece that can get missed when simply looking at revenue growth.

Tanfac isn’t just producing more HF.

It is trying to convert more of its HF into higher-value downstream products.

Illustratively, HF could have a realization of around ₹100, while converting it into R32 can take realization closer to ₹250.

The margin profile also improves as you move downstream:

Sulfuric acid → ~20% gross margin

HF → ~36% gross margin

R32 → higher still

So the opportunity isn’t merely volume growth.

It is better realization + better margins + downstream integration.

That’s where operating leverage can start becoming meaningful.

The capex is already underway:

Tanfac has announced around ₹495 crore of capex, funded entirely through a QIP.

No incremental debt.

The company is currently debt-free, which gives it a fairly clean balance sheet while it enters this next phase of growth.

FY26 revenue grew around 26–28%, although PAT margins fell from roughly 16% to 10%.

The reason?

Higher sulfur input costs and increased depreciation as the company spends on capacity.

So the near-term earnings picture isn’t as clean as the topline suggests.

But that’s also why the next 2–3 years matter more than the last quarter.

The next optionality: semiconductors

R32 could be the near-term growth engine.

But Tanfac is also working on something potentially much bigger over the longer term: electronic-grade DHF.

Semiconductor manufacturing requires extremely high-purity chemicals.

Tanfac’s current solar-grade DHF is around the 10 parts-per-billion purity level.

The target for electronic-grade DHF is around 100 parts per trillion.

That’s a massive jump in purity.

And unlike R32, this is not an immediate revenue opportunity. Customer qualification can take 12–18 months or more.

But if approved, it gives Tanfac another avenue for growth and, more importantly, reduces its dependence on a single product.

So what are the numbers saying?

Management is targeting >30% revenue growth in FY27, with margins of around 16–19%.

For FY28, topline growth guidance goes as high as ~60%.

Consensus estimates are around ₹90 crore of FY27 PAT, implying roughly 35–40% earnings growth.

The catch?

At current valuations, the stock trades at roughly 70–75x forward earnings.

That’s expensive compared with established fluorochemical names such as SRF and Navin Fluorine.

So this isn’t a cheap stock.

The market is already pricing in a meaningful part of the turnaround.

But perhaps that is exactly what makes Tanfac interesting.

The story isn’t simply “earnings are growing.”

It is: new ownership → new capex → downstream integration → R32 → margin expansion → semiconductor-grade chemicals.

If execution plays out, the business could look very different 2–3 years from now.

But there are some very real risks.

The biggest one is concentration.

R32 alone could eventually contribute close to 50% of revenue.

Then there is sulfur pricing, because the entire value chain is ultimately dependent on sulfur as an input.

And finally, there is regulatory risk. If India’s Kigali allocation is reduced in the future, some of the newly built capacity could potentially remain underutilized.

So, like most high-growth chemical stories, this isn’t a straightforward “buy because earnings are growing” story.

It’s a bet on capacity, downstream integration, and execution.